BETHESDA, Md., July 25 /PRNewswire-FirstCall/ -- Micromet, Inc. , a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases, today announced that the company will conduct a conference call and audio webcast on Wednesday, August 8, 2007, at 9:00am Eastern Time (03:00pm Central European Time) in conjunction with the release of its financial results for the second quarter ended June 30, 2007. Micromet anticipates releasing its financial results at 7:00am, Eastern Time (01:00pm Central European Time) on Wednesday, August 8, 2007.
To participate in this conference call, dial 866-713-8310 (U.S.) or 617-597-5308 (international), passcode: 97082649. The audio webcast can be accessed via the company’s website at: www.micromet-inc.com.
A replay of the call will be available from 12:00pm Eastern Time on August 9, 2007 (06:00pm Central European Time) through Thursday, August 16, 2007. The replay number is 888-286-8010 (U.S.) or 617-801-6888 (international), passcode: 82626657.
About Micromet, Inc. (www.micromet-inc.com)
Micromet, Inc. is a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases. Three product candidates are currently in clinical trials. MT103/MEDI-538, which is the first product candidate based on Micromet’s novel BiTE(R) product development platform, is being evaluated in a phase 1 clinical trial for the treatment of patients with non-Hodgkin’s lymphoma. The BiTE product development platform is based on a unique, antibody-based format that leverages the cytotoxic potential of T cells, the most powerful ‘killer cells’ of the human immune system. We are developing MT103 in collaboration with MedImmune, Inc. Our second clinical stage product candidate is adecatumumab (MT201), a recombinant human monoclonal antibody which targets EpCAM expressing tumors. Adecatumumab has completed two phase 2a clinical trials, one in patients with breast cancer and the other in patients with prostate cancer. In addition, a phase 1b trial evaluating the safety and tolerability of adecatumumab in combination with docetaxel is currently ongoing in patients with metastatic breast cancer. We are developing adecatumumab in collaboration with Merck Serono. Our third clinical stage product candidate is D93/TRC093, a first-in-class humanized monoclonal antibody that inhibits angiogenesis and tumor cell growth by binding cleaved collagen. This product candidate is in phase 1 clinical trials and is being developed by TRACON Pharmaceuticals, Inc. for the treatment of patients with cancer and Age-Related Macular Degeneration (AMD) pursuant to a license agreement under which we have granted TRACON the worldwide rights to develop and commercialize D93. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, Micromet’s human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which may be important in the treatment of inflammatory diseases, such as rheumatoid arthritis.
Micromet, Inc.
CONTACT: media, Christopher Schnittker, SVP & CFO, Micromet, Inc.,+1-240-752-1421, or christopher.schnittker@micromet-inc.com, or SusanNoonan, +1-212-966-3650, or susan@sanoonan.com, for Micromet, Inc., orinvestors, Patricia Garrison, +1-917-322-2567, or pgarrison@rxir.com, forMicromet, Inc.
Web site: http://www.micromet-inc.com/
